Funding
Seed extension · Biotech

Autoimmunity BioSolutions closes $1m seed extension

Eos BioInnovation and family-office investors back further preclinical work, bringing total seed capital to $3.1m.

Updated Oct 16, 2026By RoundOS Funding desk

Additional capital for animal and patient-sample studies

Eos BioInnovation anchored Autoimmunity BioSolutions’ $1m seed extension. Independent Capital and Elmstead Partners continued their support, and NewTech Investment Holdings joined as a new family-office investor.

The extension brings total seed capital to $3.1m. CEO Eugene Williams said the money would support animal-model work and analyses of patient biological samples in rheumatoid arthritis. These are development activities, rather than evidence of an established clinical treatment.

Funding history

Seed extension · This round$1M

Sources

  1. Autoimmunity BioSolutions financing announcementprnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related